nodes	percent_of_prediction	percent_of_DWPC	metapath
Disopyramide—CYP3A4—Ezetimibe—atherosclerosis	0.0457	0.211	CbGbCtD
Disopyramide—CYP3A4—Rosuvastatin—atherosclerosis	0.0457	0.211	CbGbCtD
Disopyramide—CYP3A4—Simvastatin—atherosclerosis	0.0425	0.196	CbGbCtD
Disopyramide—CYP3A4—Pravastatin—atherosclerosis	0.0416	0.192	CbGbCtD
Disopyramide—CYP3A4—Lovastatin—atherosclerosis	0.0416	0.192	CbGbCtD
Disopyramide—Sensation of warmth—Niacin—atherosclerosis	0.0187	0.0301	CcSEcCtD
Disopyramide—Lupus erythematosus—Lovastatin—atherosclerosis	0.0157	0.0253	CcSEcCtD
Disopyramide—Lupus erythematosus—Simvastatin—atherosclerosis	0.0147	0.0237	CcSEcCtD
Disopyramide—Lupus erythematosus—Pravastatin—atherosclerosis	0.0133	0.0214	CcSEcCtD
Disopyramide—Ache—Lovastatin—atherosclerosis	0.0127	0.0205	CcSEcCtD
Disopyramide—Ache—Simvastatin—atherosclerosis	0.0119	0.0191	CcSEcCtD
Disopyramide—Ache—Pravastatin—atherosclerosis	0.0107	0.0173	CcSEcCtD
Disopyramide—Systemic lupus erythematosus—Lovastatin—atherosclerosis	0.0106	0.0171	CcSEcCtD
Disopyramide—Systemic lupus erythematosus—Simvastatin—atherosclerosis	0.0099	0.016	CcSEcCtD
Disopyramide—Systemic lupus erythematosus—Pravastatin—atherosclerosis	0.00895	0.0144	CcSEcCtD
Disopyramide—Hepatic enzyme increased—Rosuvastatin—atherosclerosis	0.00731	0.0118	CcSEcCtD
Disopyramide—Jaundice cholestatic—Lovastatin—atherosclerosis	0.00667	0.0107	CcSEcCtD
Disopyramide—Feeling hot—Niacin—atherosclerosis	0.00641	0.0103	CcSEcCtD
Disopyramide—Tingling sensation—Niacin—atherosclerosis	0.00626	0.0101	CcSEcCtD
Disopyramide—Jaundice cholestatic—Simvastatin—atherosclerosis	0.00624	0.0101	CcSEcCtD
Disopyramide—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00618	0.00997	CcSEcCtD
Disopyramide—Numbness—Pravastatin—atherosclerosis	0.00598	0.00963	CcSEcCtD
Disopyramide—Jaundice cholestatic—Niacin—atherosclerosis	0.00573	0.00923	CcSEcCtD
Disopyramide—Sensory loss—Pravastatin—atherosclerosis	0.00572	0.00922	CcSEcCtD
Disopyramide—Jaundice cholestatic—Pravastatin—atherosclerosis	0.00564	0.00909	CcSEcCtD
Disopyramide—Pheniramine—HRH1—atherosclerosis	0.00525	0.235	CrCbGaD
Disopyramide—Gynaecomastia—Lovastatin—atherosclerosis	0.00524	0.00845	CcSEcCtD
Disopyramide—Gynaecomastia—Simvastatin—atherosclerosis	0.0049	0.0079	CcSEcCtD
Disopyramide—Clofedanol—HRH1—atherosclerosis	0.00479	0.214	CrCbGaD
Disopyramide—Gynaecomastia—Pravastatin—atherosclerosis	0.00443	0.00714	CcSEcCtD
Disopyramide—Muscular weakness—Rosuvastatin—atherosclerosis	0.00443	0.00713	CcSEcCtD
Disopyramide—Doxylamine—HRH1—atherosclerosis	0.00438	0.195	CrCbGaD
Disopyramide—Tripelennamine—HRH1—atherosclerosis	0.00416	0.186	CrCbGaD
Disopyramide—Depression—Rosuvastatin—atherosclerosis	0.00386	0.00621	CcSEcCtD
Disopyramide—Dimetindene—HRH1—atherosclerosis	0.00383	0.171	CrCbGaD
Disopyramide—Muscular weakness—Ezetimibe—atherosclerosis	0.00368	0.00593	CcSEcCtD
Disopyramide—Diplopia—Pravastatin—atherosclerosis	0.0036	0.0058	CcSEcCtD
Disopyramide—Muscular weakness—Simvastatin—atherosclerosis	0.00351	0.00565	CcSEcCtD
Disopyramide—Urinary retention—Niacin—atherosclerosis	0.00347	0.0056	CcSEcCtD
Disopyramide—Hepatitis—Rosuvastatin—atherosclerosis	0.00347	0.0056	CcSEcCtD
Disopyramide—Erectile dysfunction—Lovastatin—atherosclerosis	0.00339	0.00546	CcSEcCtD
Disopyramide—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00332	0.00535	CcSEcCtD
Disopyramide—Muscular weakness—Niacin—atherosclerosis	0.00322	0.00519	CcSEcCtD
Disopyramide—Abdominal distension—Niacin—atherosclerosis	0.00318	0.00512	CcSEcCtD
Disopyramide—Muscular weakness—Pravastatin—atherosclerosis	0.00317	0.00511	CcSEcCtD
Disopyramide—Erectile dysfunction—Simvastatin—atherosclerosis	0.00317	0.0051	CcSEcCtD
Disopyramide—Abdominal distension—Pravastatin—atherosclerosis	0.00313	0.00504	CcSEcCtD
Disopyramide—Arrhythmia—Rosuvastatin—atherosclerosis	0.0031	0.005	CcSEcCtD
Disopyramide—Depression—Simvastatin—atherosclerosis	0.00306	0.00493	CcSEcCtD
Disopyramide—Sweating increased—Pravastatin—atherosclerosis	0.00303	0.00488	CcSEcCtD
Disopyramide—Flatulence—Rosuvastatin—atherosclerosis	0.00298	0.0048	CcSEcCtD
Disopyramide—Hepatitis—Lovastatin—atherosclerosis	0.00294	0.00474	CcSEcCtD
Disopyramide—Erectile dysfunction—Niacin—atherosclerosis	0.00291	0.00469	CcSEcCtD
Disopyramide—Dysuria—Pravastatin—atherosclerosis	0.00291	0.00468	CcSEcCtD
Disopyramide—Hepatitis—Ezetimibe—atherosclerosis	0.00289	0.00465	CcSEcCtD
Disopyramide—Erectile dysfunction—Pravastatin—atherosclerosis	0.00286	0.00461	CcSEcCtD
Disopyramide—Weight increased—Pravastatin—atherosclerosis	0.00283	0.00456	CcSEcCtD
Disopyramide—Depression—Pravastatin—atherosclerosis	0.00276	0.00445	CcSEcCtD
Disopyramide—Angioedema—Rosuvastatin—atherosclerosis	0.00276	0.00445	CcSEcCtD
Disopyramide—Hepatitis—Simvastatin—atherosclerosis	0.00275	0.00444	CcSEcCtD
Disopyramide—Hepatitis—Niacin—atherosclerosis	0.00253	0.00407	CcSEcCtD
Disopyramide—Flatulence—Lovastatin—atherosclerosis	0.00252	0.00407	CcSEcCtD
Disopyramide—Hypoaesthesia—Niacin—atherosclerosis	0.00251	0.00405	CcSEcCtD
Disopyramide—Dysgeusia—Lovastatin—atherosclerosis	0.00251	0.00404	CcSEcCtD
Disopyramide—Hepatitis—Pravastatin—atherosclerosis	0.00249	0.00401	CcSEcCtD
Disopyramide—Confusional state—Rosuvastatin—atherosclerosis	0.00249	0.00401	CcSEcCtD
Disopyramide—Hypoaesthesia—Pravastatin—atherosclerosis	0.00248	0.00399	CcSEcCtD
Disopyramide—Flatulence—Ezetimibe—atherosclerosis	0.00248	0.00399	CcSEcCtD
Disopyramide—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00241	0.00389	CcSEcCtD
Disopyramide—Vision blurred—Lovastatin—atherosclerosis	0.00241	0.00389	CcSEcCtD
Disopyramide—Ill-defined disorder—Lovastatin—atherosclerosis	0.00238	0.00383	CcSEcCtD
Disopyramide—Flatulence—Simvastatin—atherosclerosis	0.00236	0.0038	CcSEcCtD
Disopyramide—Dysgeusia—Simvastatin—atherosclerosis	0.00235	0.00378	CcSEcCtD
Disopyramide—Angioedema—Lovastatin—atherosclerosis	0.00234	0.00377	CcSEcCtD
Disopyramide—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00233	0.00376	CcSEcCtD
Disopyramide—Malaise—Lovastatin—atherosclerosis	0.00231	0.00372	CcSEcCtD
Disopyramide—Vertigo—Lovastatin—atherosclerosis	0.0023	0.00371	CcSEcCtD
Disopyramide—Angioedema—Ezetimibe—atherosclerosis	0.0023	0.0037	CcSEcCtD
Disopyramide—Malaise—Ezetimibe—atherosclerosis	0.00227	0.00365	CcSEcCtD
Disopyramide—Vision blurred—Simvastatin—atherosclerosis	0.00226	0.00364	CcSEcCtD
Disopyramide—Arrhythmia—Niacin—atherosclerosis	0.00226	0.00364	CcSEcCtD
Disopyramide—Insomnia—Rosuvastatin—atherosclerosis	0.00223	0.0036	CcSEcCtD
Disopyramide—Ill-defined disorder—Simvastatin—atherosclerosis	0.00222	0.00358	CcSEcCtD
Disopyramide—Arrhythmia—Pravastatin—atherosclerosis	0.00222	0.00358	CcSEcCtD
Disopyramide—Paraesthesia—Rosuvastatin—atherosclerosis	0.00221	0.00357	CcSEcCtD
Disopyramide—Angioedema—Simvastatin—atherosclerosis	0.00219	0.00353	CcSEcCtD
Disopyramide—Chest pain—Lovastatin—atherosclerosis	0.00218	0.00351	CcSEcCtD
Disopyramide—Dyspepsia—Rosuvastatin—atherosclerosis	0.00217	0.0035	CcSEcCtD
Disopyramide—Flatulence—Niacin—atherosclerosis	0.00217	0.00349	CcSEcCtD
Disopyramide—Malaise—Simvastatin—atherosclerosis	0.00216	0.00348	CcSEcCtD
Disopyramide—Tension—Niacin—atherosclerosis	0.00216	0.00348	CcSEcCtD
Disopyramide—Discomfort—Lovastatin—atherosclerosis	0.00215	0.00347	CcSEcCtD
Disopyramide—Vertigo—Simvastatin—atherosclerosis	0.00215	0.00347	CcSEcCtD
Disopyramide—Chest pain—Ezetimibe—atherosclerosis	0.00214	0.00345	CcSEcCtD
Disopyramide—Nervousness—Niacin—atherosclerosis	0.00214	0.00344	CcSEcCtD
Disopyramide—Flatulence—Pravastatin—atherosclerosis	0.00213	0.00344	CcSEcCtD
Disopyramide—Dry mouth—Lovastatin—atherosclerosis	0.00213	0.00344	CcSEcCtD
Disopyramide—Tension—Pravastatin—atherosclerosis	0.00213	0.00343	CcSEcCtD
Disopyramide—Dysgeusia—Pravastatin—atherosclerosis	0.00212	0.00342	CcSEcCtD
Disopyramide—Discomfort—Ezetimibe—atherosclerosis	0.00211	0.00341	CcSEcCtD
Disopyramide—Pain—Rosuvastatin—atherosclerosis	0.00211	0.0034	CcSEcCtD
Disopyramide—Constipation—Rosuvastatin—atherosclerosis	0.00211	0.0034	CcSEcCtD
Disopyramide—Confusional state—Lovastatin—atherosclerosis	0.00211	0.0034	CcSEcCtD
Disopyramide—Nervousness—Pravastatin—atherosclerosis	0.0021	0.00339	CcSEcCtD
Disopyramide—Dry mouth—Ezetimibe—atherosclerosis	0.00209	0.00337	CcSEcCtD
Disopyramide—Vision blurred—Niacin—atherosclerosis	0.00207	0.00334	CcSEcCtD
Disopyramide—Confusional state—Ezetimibe—atherosclerosis	0.00207	0.00333	CcSEcCtD
Disopyramide—Thrombocytopenia—Lovastatin—atherosclerosis	0.00205	0.0033	CcSEcCtD
Disopyramide—Vision blurred—Pravastatin—atherosclerosis	0.00204	0.00329	CcSEcCtD
Disopyramide—Chest pain—Simvastatin—atherosclerosis	0.00204	0.00329	CcSEcCtD
Disopyramide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00203	0.00328	CcSEcCtD
Disopyramide—Discomfort—Simvastatin—atherosclerosis	0.00201	0.00325	CcSEcCtD
Disopyramide—Angioedema—Niacin—atherosclerosis	0.00201	0.00324	CcSEcCtD
Disopyramide—Ill-defined disorder—Pravastatin—atherosclerosis	0.00201	0.00324	CcSEcCtD
Disopyramide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00201	0.00324	CcSEcCtD
Disopyramide—Anorexia—Lovastatin—atherosclerosis	0.00199	0.00321	CcSEcCtD
Disopyramide—Skin disorder—Ezetimibe—atherosclerosis	0.00199	0.00321	CcSEcCtD
Disopyramide—Angioedema—Pravastatin—atherosclerosis	0.00198	0.00319	CcSEcCtD
Disopyramide—Vertigo—Niacin—atherosclerosis	0.00198	0.00319	CcSEcCtD
Disopyramide—Syncope—Niacin—atherosclerosis	0.00197	0.00318	CcSEcCtD
Disopyramide—Confusional state—Simvastatin—atherosclerosis	0.00197	0.00318	CcSEcCtD
Disopyramide—Urticaria—Rosuvastatin—atherosclerosis	0.00196	0.00316	CcSEcCtD
Disopyramide—Oedema—Simvastatin—atherosclerosis	0.00195	0.00315	CcSEcCtD
Disopyramide—Malaise—Pravastatin—atherosclerosis	0.00195	0.00315	CcSEcCtD
Disopyramide—Vertigo—Pravastatin—atherosclerosis	0.00195	0.00314	CcSEcCtD
Disopyramide—Loss of consciousness—Niacin—atherosclerosis	0.00193	0.00312	CcSEcCtD
Disopyramide—Thrombocytopenia—Simvastatin—atherosclerosis	0.00191	0.00309	CcSEcCtD
Disopyramide—Insomnia—Lovastatin—atherosclerosis	0.00189	0.00305	CcSEcCtD
Disopyramide—Paraesthesia—Lovastatin—atherosclerosis	0.00188	0.00302	CcSEcCtD
Disopyramide—Anorexia—Simvastatin—atherosclerosis	0.00186	0.003	CcSEcCtD
Disopyramide—Dyspnoea—Lovastatin—atherosclerosis	0.00186	0.003	CcSEcCtD
Disopyramide—Insomnia—Ezetimibe—atherosclerosis	0.00185	0.00299	CcSEcCtD
Disopyramide—Chest pain—Pravastatin—atherosclerosis	0.00184	0.00297	CcSEcCtD
Disopyramide—Paraesthesia—Ezetimibe—atherosclerosis	0.00184	0.00297	CcSEcCtD
Disopyramide—Dyspepsia—Lovastatin—atherosclerosis	0.00184	0.00297	CcSEcCtD
Disopyramide—Dry mouth—Niacin—atherosclerosis	0.00183	0.00295	CcSEcCtD
Disopyramide—Dyspnoea—Ezetimibe—atherosclerosis	0.00183	0.00295	CcSEcCtD
Disopyramide—Discomfort—Pravastatin—atherosclerosis	0.00182	0.00294	CcSEcCtD
Disopyramide—Decreased appetite—Lovastatin—atherosclerosis	0.00182	0.00293	CcSEcCtD
Disopyramide—Dyspepsia—Ezetimibe—atherosclerosis	0.0018	0.00291	CcSEcCtD
Disopyramide—Fatigue—Lovastatin—atherosclerosis	0.0018	0.0029	CcSEcCtD
Disopyramide—Oedema—Niacin—atherosclerosis	0.0018	0.00289	CcSEcCtD
Disopyramide—Constipation—Lovastatin—atherosclerosis	0.00179	0.00288	CcSEcCtD
Disopyramide—Pain—Lovastatin—atherosclerosis	0.00179	0.00288	CcSEcCtD
Disopyramide—Confusional state—Pravastatin—atherosclerosis	0.00178	0.00287	CcSEcCtD
Disopyramide—Decreased appetite—Ezetimibe—atherosclerosis	0.00178	0.00287	CcSEcCtD
Disopyramide—Asthenia—Rosuvastatin—atherosclerosis	0.00177	0.00285	CcSEcCtD
Disopyramide—Insomnia—Simvastatin—atherosclerosis	0.00177	0.00285	CcSEcCtD
Disopyramide—Oedema—Pravastatin—atherosclerosis	0.00177	0.00285	CcSEcCtD
Disopyramide—Fatigue—Ezetimibe—atherosclerosis	0.00177	0.00285	CcSEcCtD
Disopyramide—Shock—Niacin—atherosclerosis	0.00177	0.00285	CcSEcCtD
Disopyramide—Paraesthesia—Simvastatin—atherosclerosis	0.00176	0.00283	CcSEcCtD
Disopyramide—Constipation—Ezetimibe—atherosclerosis	0.00175	0.00283	CcSEcCtD
Disopyramide—Pain—Ezetimibe—atherosclerosis	0.00175	0.00283	CcSEcCtD
Disopyramide—Pruritus—Rosuvastatin—atherosclerosis	0.00174	0.00281	CcSEcCtD
Disopyramide—Skin disorder—Niacin—atherosclerosis	0.00174	0.00281	CcSEcCtD
Disopyramide—Dyspnoea—Simvastatin—atherosclerosis	0.00174	0.00281	CcSEcCtD
Disopyramide—Hyperhidrosis—Niacin—atherosclerosis	0.00174	0.0028	CcSEcCtD
Disopyramide—Thrombocytopenia—Pravastatin—atherosclerosis	0.00173	0.00279	CcSEcCtD
Disopyramide—Feeling abnormal—Lovastatin—atherosclerosis	0.00172	0.00278	CcSEcCtD
Disopyramide—Dyspepsia—Simvastatin—atherosclerosis	0.00172	0.00277	CcSEcCtD
Disopyramide—Anorexia—Niacin—atherosclerosis	0.00171	0.00276	CcSEcCtD
Disopyramide—Hyperhidrosis—Pravastatin—atherosclerosis	0.00171	0.00275	CcSEcCtD
Disopyramide—Decreased appetite—Simvastatin—atherosclerosis	0.0017	0.00274	CcSEcCtD
Disopyramide—Feeling abnormal—Ezetimibe—atherosclerosis	0.00169	0.00272	CcSEcCtD
Disopyramide—Diarrhoea—Rosuvastatin—atherosclerosis	0.00169	0.00272	CcSEcCtD
Disopyramide—Fatigue—Simvastatin—atherosclerosis	0.00169	0.00272	CcSEcCtD
Disopyramide—Anorexia—Pravastatin—atherosclerosis	0.00168	0.00272	CcSEcCtD
Disopyramide—Hypotension—Niacin—atherosclerosis	0.00168	0.0027	CcSEcCtD
Disopyramide—Pain—Simvastatin—atherosclerosis	0.00167	0.00269	CcSEcCtD
Disopyramide—Constipation—Simvastatin—atherosclerosis	0.00167	0.00269	CcSEcCtD
Disopyramide—Urticaria—Lovastatin—atherosclerosis	0.00166	0.00268	CcSEcCtD
Disopyramide—Body temperature increased—Lovastatin—atherosclerosis	0.00165	0.00266	CcSEcCtD
Disopyramide—Dizziness—Rosuvastatin—atherosclerosis	0.00163	0.00263	CcSEcCtD
Disopyramide—Urticaria—Ezetimibe—atherosclerosis	0.00163	0.00262	CcSEcCtD
Disopyramide—Insomnia—Niacin—atherosclerosis	0.00162	0.00262	CcSEcCtD
Disopyramide—Body temperature increased—Ezetimibe—atherosclerosis	0.00162	0.00261	CcSEcCtD
Disopyramide—Paraesthesia—Niacin—atherosclerosis	0.00161	0.0026	CcSEcCtD
Disopyramide—Feeling abnormal—Simvastatin—atherosclerosis	0.00161	0.0026	CcSEcCtD
Disopyramide—Dyspnoea—Niacin—atherosclerosis	0.0016	0.00258	CcSEcCtD
Disopyramide—Insomnia—Pravastatin—atherosclerosis	0.0016	0.00258	CcSEcCtD
Disopyramide—Somnolence—Niacin—atherosclerosis	0.0016	0.00257	CcSEcCtD
Disopyramide—Paraesthesia—Pravastatin—atherosclerosis	0.00159	0.00256	CcSEcCtD
Disopyramide—Dyspepsia—Niacin—atherosclerosis	0.00158	0.00255	CcSEcCtD
Disopyramide—Dyspnoea—Pravastatin—atherosclerosis	0.00158	0.00254	CcSEcCtD
Disopyramide—Decreased appetite—Niacin—atherosclerosis	0.00156	0.00252	CcSEcCtD
Disopyramide—Dyspepsia—Pravastatin—atherosclerosis	0.00156	0.00251	CcSEcCtD
Disopyramide—Rash—Rosuvastatin—atherosclerosis	0.00156	0.00251	CcSEcCtD
Disopyramide—Dermatitis—Rosuvastatin—atherosclerosis	0.00155	0.0025	CcSEcCtD
Disopyramide—Urticaria—Simvastatin—atherosclerosis	0.00155	0.0025	CcSEcCtD
Disopyramide—Body temperature increased—Simvastatin—atherosclerosis	0.00155	0.00249	CcSEcCtD
Disopyramide—Headache—Rosuvastatin—atherosclerosis	0.00155	0.00249	CcSEcCtD
Disopyramide—Decreased appetite—Pravastatin—atherosclerosis	0.00154	0.00248	CcSEcCtD
Disopyramide—Pain—Niacin—atherosclerosis	0.00154	0.00247	CcSEcCtD
Disopyramide—Fatigue—Pravastatin—atherosclerosis	0.00152	0.00246	CcSEcCtD
Disopyramide—Constipation—Pravastatin—atherosclerosis	0.00151	0.00244	CcSEcCtD
Disopyramide—Pain—Pravastatin—atherosclerosis	0.00151	0.00244	CcSEcCtD
Disopyramide—Asthenia—Lovastatin—atherosclerosis	0.0015	0.00242	CcSEcCtD
Disopyramide—Pruritus—Lovastatin—atherosclerosis	0.00148	0.00238	CcSEcCtD
Disopyramide—Asthenia—Ezetimibe—atherosclerosis	0.00147	0.00237	CcSEcCtD
Disopyramide—Nausea—Rosuvastatin—atherosclerosis	0.00146	0.00236	CcSEcCtD
Disopyramide—Feeling abnormal—Pravastatin—atherosclerosis	0.00146	0.00235	CcSEcCtD
Disopyramide—Pruritus—Ezetimibe—atherosclerosis	0.00145	0.00234	CcSEcCtD
Disopyramide—Diarrhoea—Lovastatin—atherosclerosis	0.00143	0.0023	CcSEcCtD
Disopyramide—Urticaria—Niacin—atherosclerosis	0.00143	0.0023	CcSEcCtD
Disopyramide—Body temperature increased—Niacin—atherosclerosis	0.00142	0.00229	CcSEcCtD
Disopyramide—Urticaria—Pravastatin—atherosclerosis	0.0014	0.00226	CcSEcCtD
Disopyramide—Asthenia—Simvastatin—atherosclerosis	0.0014	0.00226	CcSEcCtD
Disopyramide—Diarrhoea—Ezetimibe—atherosclerosis	0.0014	0.00226	CcSEcCtD
Disopyramide—Body temperature increased—Pravastatin—atherosclerosis	0.0014	0.00225	CcSEcCtD
Disopyramide—Pruritus—Simvastatin—atherosclerosis	0.00138	0.00223	CcSEcCtD
Disopyramide—Dizziness—Lovastatin—atherosclerosis	0.00138	0.00223	CcSEcCtD
Disopyramide—Dizziness—Ezetimibe—atherosclerosis	0.00136	0.00218	CcSEcCtD
Disopyramide—Diarrhoea—Simvastatin—atherosclerosis	0.00134	0.00216	CcSEcCtD
Disopyramide—Vomiting—Lovastatin—atherosclerosis	0.00133	0.00214	CcSEcCtD
Disopyramide—Rash—Lovastatin—atherosclerosis	0.00132	0.00212	CcSEcCtD
Disopyramide—Dermatitis—Lovastatin—atherosclerosis	0.00132	0.00212	CcSEcCtD
Disopyramide—Headache—Lovastatin—atherosclerosis	0.00131	0.00211	CcSEcCtD
Disopyramide—Vomiting—Ezetimibe—atherosclerosis	0.0013	0.0021	CcSEcCtD
Disopyramide—Dizziness—Simvastatin—atherosclerosis	0.00129	0.00208	CcSEcCtD
Disopyramide—Rash—Ezetimibe—atherosclerosis	0.00129	0.00208	CcSEcCtD
Disopyramide—Dermatitis—Ezetimibe—atherosclerosis	0.00129	0.00208	CcSEcCtD
Disopyramide—Asthenia—Niacin—atherosclerosis	0.00129	0.00208	CcSEcCtD
Disopyramide—Headache—Ezetimibe—atherosclerosis	0.00128	0.00207	CcSEcCtD
Disopyramide—Pruritus—Niacin—atherosclerosis	0.00127	0.00205	CcSEcCtD
Disopyramide—Asthenia—Pravastatin—atherosclerosis	0.00127	0.00204	CcSEcCtD
Disopyramide—Pruritus—Pravastatin—atherosclerosis	0.00125	0.00202	CcSEcCtD
Disopyramide—Vomiting—Simvastatin—atherosclerosis	0.00124	0.002	CcSEcCtD
Disopyramide—Nausea—Lovastatin—atherosclerosis	0.00124	0.002	CcSEcCtD
Disopyramide—Rash—Simvastatin—atherosclerosis	0.00123	0.00199	CcSEcCtD
Disopyramide—Dermatitis—Simvastatin—atherosclerosis	0.00123	0.00198	CcSEcCtD
Disopyramide—Diarrhoea—Niacin—atherosclerosis	0.00123	0.00198	CcSEcCtD
Disopyramide—Headache—Simvastatin—atherosclerosis	0.00122	0.00197	CcSEcCtD
Disopyramide—Nausea—Ezetimibe—atherosclerosis	0.00122	0.00196	CcSEcCtD
Disopyramide—Diarrhoea—Pravastatin—atherosclerosis	0.00121	0.00195	CcSEcCtD
Disopyramide—Dizziness—Niacin—atherosclerosis	0.00119	0.00191	CcSEcCtD
Disopyramide—Dizziness—Pravastatin—atherosclerosis	0.00117	0.00188	CcSEcCtD
Disopyramide—Nausea—Simvastatin—atherosclerosis	0.00116	0.00187	CcSEcCtD
Disopyramide—Vomiting—Niacin—atherosclerosis	0.00114	0.00184	CcSEcCtD
Disopyramide—Rash—Niacin—atherosclerosis	0.00113	0.00182	CcSEcCtD
Disopyramide—Dermatitis—Niacin—atherosclerosis	0.00113	0.00182	CcSEcCtD
Disopyramide—Headache—Niacin—atherosclerosis	0.00112	0.00181	CcSEcCtD
Disopyramide—Vomiting—Pravastatin—atherosclerosis	0.00112	0.00181	CcSEcCtD
Disopyramide—Rash—Pravastatin—atherosclerosis	0.00111	0.0018	CcSEcCtD
Disopyramide—Dermatitis—Pravastatin—atherosclerosis	0.00111	0.00179	CcSEcCtD
Disopyramide—Headache—Pravastatin—atherosclerosis	0.00111	0.00178	CcSEcCtD
Disopyramide—Nausea—Niacin—atherosclerosis	0.00107	0.00172	CcSEcCtD
Disopyramide—Nausea—Pravastatin—atherosclerosis	0.00105	0.00169	CcSEcCtD
Disopyramide—CHRM1—Signaling Pathways—CYBA—atherosclerosis	4.23e-05	0.000302	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CYBA—atherosclerosis	4.22e-05	0.000301	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCR2—atherosclerosis	4.2e-05	0.0003	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EDNRA—atherosclerosis	4.2e-05	0.0003	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—HMOX1—atherosclerosis	4.2e-05	0.000299	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—GSTM1—atherosclerosis	4.19e-05	0.000299	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—PIK3CG—atherosclerosis	4.19e-05	0.000299	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—PIK3CG—atherosclerosis	4.18e-05	0.000298	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CYBA—atherosclerosis	4.18e-05	0.000298	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PARP1—atherosclerosis	4.14e-05	0.000296	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—GHRL—atherosclerosis	4.14e-05	0.000296	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PLAT—atherosclerosis	4.14e-05	0.000296	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—PIK3CG—atherosclerosis	4.14e-05	0.000295	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PLAT—atherosclerosis	4.13e-05	0.000295	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PARP1—atherosclerosis	4.13e-05	0.000295	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—GHRL—atherosclerosis	4.13e-05	0.000295	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—LPL—atherosclerosis	4.12e-05	0.000294	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PLAT—atherosclerosis	4.09e-05	0.000292	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—GHRL—atherosclerosis	4.09e-05	0.000292	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PARP1—atherosclerosis	4.09e-05	0.000292	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—APOB—atherosclerosis	4.02e-05	0.000287	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—GPX1—atherosclerosis	4.02e-05	0.000287	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—F2—atherosclerosis	3.98e-05	0.000284	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—F2—atherosclerosis	3.97e-05	0.000283	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—F2—atherosclerosis	3.93e-05	0.00028	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—CD36—atherosclerosis	3.91e-05	0.000279	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—GSTM1—atherosclerosis	3.91e-05	0.000279	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—HMOX1—atherosclerosis	3.88e-05	0.000277	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—LPL—atherosclerosis	3.84e-05	0.000274	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—PIK3CG—atherosclerosis	3.81e-05	0.000272	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—PIK3CG—atherosclerosis	3.8e-05	0.000271	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCG1—atherosclerosis	3.77e-05	0.000269	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CG—atherosclerosis	3.76e-05	0.000268	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—GPX1—atherosclerosis	3.74e-05	0.000267	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—APOB—atherosclerosis	3.71e-05	0.000265	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—MTHFR—atherosclerosis	3.71e-05	0.000265	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—CD36—atherosclerosis	3.65e-05	0.00026	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PPARA—atherosclerosis	3.64e-05	0.00026	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KNG1—atherosclerosis	3.64e-05	0.00026	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KNG1—atherosclerosis	3.62e-05	0.000259	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AGTR1—atherosclerosis	3.61e-05	0.000258	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—GSTM1—atherosclerosis	3.61e-05	0.000258	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AGTR1—atherosclerosis	3.6e-05	0.000257	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KNG1—atherosclerosis	3.59e-05	0.000256	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AGTR1—atherosclerosis	3.57e-05	0.000255	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—CCL2—atherosclerosis	3.55e-05	0.000253	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—LCAT—atherosclerosis	3.55e-05	0.000253	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—FABP4—atherosclerosis	3.55e-05	0.000253	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—LPL—atherosclerosis	3.54e-05	0.000253	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—CCL2—atherosclerosis	3.53e-05	0.000252	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PLG—atherosclerosis	3.52e-05	0.000251	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—AGT—atherosclerosis	3.52e-05	0.000251	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PLG—atherosclerosis	3.51e-05	0.000251	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—CCL2—atherosclerosis	3.5e-05	0.00025	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOA4—atherosclerosis	3.48e-05	0.000248	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PLG—atherosclerosis	3.48e-05	0.000248	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—GPX1—atherosclerosis	3.46e-05	0.000247	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—MTHFR—atherosclerosis	3.45e-05	0.000247	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—APOE—atherosclerosis	3.45e-05	0.000246	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP7A1—atherosclerosis	3.42e-05	0.000244	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—CAV1—atherosclerosis	3.42e-05	0.000244	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—APOA1—atherosclerosis	3.41e-05	0.000243	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PPARA—atherosclerosis	3.39e-05	0.000242	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—CD36—atherosclerosis	3.37e-05	0.00024	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SOCS3—atherosclerosis	3.34e-05	0.000238	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SOCS3—atherosclerosis	3.33e-05	0.000237	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SOCS3—atherosclerosis	3.29e-05	0.000235	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—AGT—atherosclerosis	3.28e-05	0.000234	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MMP3—atherosclerosis	3.22e-05	0.00023	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—APOE—atherosclerosis	3.22e-05	0.00023	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MMP3—atherosclerosis	3.21e-05	0.000229	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IGF2—atherosclerosis	3.21e-05	0.000229	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IGF2—atherosclerosis	3.2e-05	0.000228	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—MTHFR—atherosclerosis	3.19e-05	0.000228	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—CAV1—atherosclerosis	3.19e-05	0.000227	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MMP3—atherosclerosis	3.18e-05	0.000227	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—APOA1—atherosclerosis	3.18e-05	0.000227	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IGF2—atherosclerosis	3.17e-05	0.000226	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP27A1—atherosclerosis	3.16e-05	0.000226	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PPARA—atherosclerosis	3.13e-05	0.000223	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CG—atherosclerosis	3.11e-05	0.000222	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—APOB—atherosclerosis	3.11e-05	0.000222	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—APOB—atherosclerosis	3.1e-05	0.000222	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—CXCL8—atherosclerosis	3.09e-05	0.00022	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—CXCL8—atherosclerosis	3.08e-05	0.00022	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—APOB—atherosclerosis	3.07e-05	0.000219	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EDN1—atherosclerosis	3.06e-05	0.000219	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EDN1—atherosclerosis	3.05e-05	0.000218	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—CXCL8—atherosclerosis	3.05e-05	0.000218	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CCL5—atherosclerosis	3.04e-05	0.000217	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—AGT—atherosclerosis	3.03e-05	0.000216	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CCL5—atherosclerosis	3.03e-05	0.000216	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EDN1—atherosclerosis	3.02e-05	0.000216	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PPARG—atherosclerosis	3.01e-05	0.000215	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCL5—atherosclerosis	3e-05	0.000214	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	3e-05	0.000214	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOA2—atherosclerosis	3e-05	0.000214	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	3e-05	0.000214	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALOX15—atherosclerosis	3e-05	0.000214	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—LPL—atherosclerosis	2.97e-05	0.000212	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—APOE—atherosclerosis	2.97e-05	0.000212	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—LPL—atherosclerosis	2.96e-05	0.000212	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.96e-05	0.000211	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—INS—atherosclerosis	2.95e-05	0.00021	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—CAV1—atherosclerosis	2.94e-05	0.00021	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—APOA1—atherosclerosis	2.94e-05	0.00021	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—LPL—atherosclerosis	2.93e-05	0.000209	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CG—atherosclerosis	2.9e-05	0.000207	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PRKCG—atherosclerosis	2.89e-05	0.000206	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PRKCG—atherosclerosis	2.88e-05	0.000206	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—LPA—atherosclerosis	2.86e-05	0.000204	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PRKCG—atherosclerosis	2.85e-05	0.000204	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SPP1—atherosclerosis	2.82e-05	0.000201	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SPP1—atherosclerosis	2.81e-05	0.0002	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	2.8e-05	0.0002	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PPARG—atherosclerosis	2.8e-05	0.0002	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—CXCL8—atherosclerosis	2.79e-05	0.000199	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SPP1—atherosclerosis	2.78e-05	0.000198	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—BGN—atherosclerosis	2.77e-05	0.000198	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—CXCL8—atherosclerosis	2.77e-05	0.000198	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—INS—atherosclerosis	2.75e-05	0.000196	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOA5—atherosclerosis	2.74e-05	0.000196	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—ALB—atherosclerosis	2.7e-05	0.000193	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CG—atherosclerosis	2.68e-05	0.000191	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2.64e-05	0.000188	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	2.61e-05	0.000186	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PDGFB—atherosclerosis	2.6e-05	0.000185	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PPARG—atherosclerosis	2.59e-05	0.000185	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—NOS3—atherosclerosis	2.59e-05	0.000185	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PDGFB—atherosclerosis	2.57e-05	0.000184	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALOX5—atherosclerosis	2.55e-05	0.000182	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AGT—atherosclerosis	2.54e-05	0.000182	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—INS—atherosclerosis	2.54e-05	0.000181	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AGT—atherosclerosis	2.54e-05	0.000181	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—ALB—atherosclerosis	2.52e-05	0.00018	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AGT—atherosclerosis	2.51e-05	0.000179	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—LEP—atherosclerosis	2.49e-05	0.000178	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—APOE—atherosclerosis	2.49e-05	0.000178	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—APOE—atherosclerosis	2.48e-05	0.000177	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—LEP—atherosclerosis	2.48e-05	0.000177	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CAV1—atherosclerosis	2.47e-05	0.000176	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—APOA1—atherosclerosis	2.46e-05	0.000176	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CAV1—atherosclerosis	2.46e-05	0.000176	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—LEP—atherosclerosis	2.46e-05	0.000176	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—APOE—atherosclerosis	2.46e-05	0.000176	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—APOA1—atherosclerosis	2.46e-05	0.000175	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CAV1—atherosclerosis	2.44e-05	0.000174	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—APOA1—atherosclerosis	2.43e-05	0.000174	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—NOS3—atherosclerosis	2.41e-05	0.000172	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ESR1—atherosclerosis	2.38e-05	0.00017	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ESR1—atherosclerosis	2.37e-05	0.000169	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTGS2—atherosclerosis	2.36e-05	0.000169	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—F2—atherosclerosis	2.35e-05	0.000168	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ESR1—atherosclerosis	2.35e-05	0.000168	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—F2—atherosclerosis	2.34e-05	0.000167	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—ALB—atherosclerosis	2.33e-05	0.000166	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—F2—atherosclerosis	2.32e-05	0.000166	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.28e-05	0.000163	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—LIPC—atherosclerosis	2.27e-05	0.000162	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOC3—atherosclerosis	2.26e-05	0.000161	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	2.25e-05	0.000161	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—LDLR—atherosclerosis	2.24e-05	0.00016	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CG—atherosclerosis	2.24e-05	0.00016	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—NOS3—atherosclerosis	2.23e-05	0.000159	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CG—atherosclerosis	2.22e-05	0.000158	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTGS2—atherosclerosis	2.2e-05	0.000157	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CETP—atherosclerosis	2.19e-05	0.000156	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	2.15e-05	0.000154	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—MAPK3—atherosclerosis	2.15e-05	0.000153	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—INS—atherosclerosis	2.13e-05	0.000152	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—MAPK3—atherosclerosis	2.13e-05	0.000152	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—INS—atherosclerosis	2.12e-05	0.000151	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—INS—atherosclerosis	2.1e-05	0.00015	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SCARB1—atherosclerosis	2.1e-05	0.00015	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CCL2—atherosclerosis	2.09e-05	0.00015	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CCL2—atherosclerosis	2.09e-05	0.000149	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCL2—atherosclerosis	2.07e-05	0.000148	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IGF1—atherosclerosis	2.06e-05	0.000147	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IGF1—atherosclerosis	2.05e-05	0.000147	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTGS2—atherosclerosis	2.04e-05	0.000145	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IGF1—atherosclerosis	2.03e-05	0.000145	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.98e-05	0.000141	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	1.96e-05	0.00014	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	1.95e-05	0.000139	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	1.93e-05	0.000138	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NOS3—atherosclerosis	1.87e-05	0.000133	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NOS3—atherosclerosis	1.86e-05	0.000133	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NOS3—atherosclerosis	1.84e-05	0.000132	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.77e-05	0.000126	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	1.66e-05	0.000118	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	1.65e-05	0.000118	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	1.63e-05	0.000117	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	1.6e-05	0.000114	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	1.59e-05	0.000114	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	1.58e-05	0.000113	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL6—atherosclerosis	1.57e-05	0.000112	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL6—atherosclerosis	1.57e-05	0.000112	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL6—atherosclerosis	1.55e-05	0.000111	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.51e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MMP9—atherosclerosis	1.5e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MMP9—atherosclerosis	1.49e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	1.48e-05	0.000106	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MMP9—atherosclerosis	1.48e-05	0.000106	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	1.48e-05	0.000105	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	1.46e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	1.46e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	1.45e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	1.45e-05	0.000104	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOB—atherosclerosis	1.45e-05	0.000104	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	1.45e-05	0.000103	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	1.44e-05	0.000103	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	1.43e-05	0.000102	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.41e-05	0.000101	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—LPL—atherosclerosis	1.39e-05	9.89e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GPX1—atherosclerosis	1.35e-05	9.65e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	1.35e-05	9.6e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	1.34e-05	9.57e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—STAT3—atherosclerosis	1.33e-05	9.51e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	1.33e-05	9.48e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—STAT3—atherosclerosis	1.33e-05	9.48e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CD36—atherosclerosis	1.32e-05	9.4e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—STAT3—atherosclerosis	1.31e-05	9.38e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	1.27e-05	9.08e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	1.27e-05	9.05e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	1.26e-05	8.97e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.25e-05	8.9e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	1.23e-05	8.81e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	1.23e-05	8.78e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PPARA—atherosclerosis	1.22e-05	8.74e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	1.22e-05	8.7e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—AKT1—atherosclerosis	1.19e-05	8.48e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—AGT—atherosclerosis	1.19e-05	8.46e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOE—atherosclerosis	1.16e-05	8.29e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CAV1—atherosclerosis	1.15e-05	8.21e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOA1—atherosclerosis	1.15e-05	8.19e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—AKT1—atherosclerosis	1.11e-05	7.91e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.05e-05	7.48e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—AKT1—atherosclerosis	1.02e-05	7.3e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PPARG—atherosclerosis	1.01e-05	7.22e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—INS—atherosclerosis	9.92e-06	7.08e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL6—atherosclerosis	9.3e-06	6.64e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL6—atherosclerosis	9.27e-06	6.62e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL6—atherosclerosis	9.18e-06	6.55e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALB—atherosclerosis	9.1e-06	6.49e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NOS3—atherosclerosis	8.7e-06	6.21e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AKT1—atherosclerosis	8.58e-06	6.13e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AKT1—atherosclerosis	8.55e-06	6.11e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AKT1—atherosclerosis	8.47e-06	6.05e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTGS2—atherosclerosis	7.96e-06	5.68e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—AKT1—atherosclerosis	4e-06	2.85e-05	CbGpPWpGaD
